Buchumschlag

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease/chronic infantile neurological cutaneous and articular syndrome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kümmerle-Deschner, Jasmin (VerfasserIn) , Ramos, Eduardo (VerfasserIn) , Blank, Norbert (VerfasserIn) , Roesler, Joachim (VerfasserIn) , Felix, Sandra D. (VerfasserIn) , Jung, Thomas (VerfasserIn) , Stricker, Kirstin (VerfasserIn) , Chakraborty, Abhijit (VerfasserIn) , Tannenbaum, Stacey (VerfasserIn) , Wright, Andrew M. (VerfasserIn) , Rordorf, Christiane (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 February 2011
In: Arthritis Research & Therapy
Year: 2011, Jahrgang: 13, Pages: 1-10
ISSN:1465-9913
DOI:10.1186/ar3266
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/ar3266
Volltext
Verfasserangaben:Jasmin B. Kuemmerle-Deschner, Eduardo Ramos, Norbert Blank, Joachim Roesler, Sandra D. Felix, Thomas Jung, Kirstin Stricker, Abhijit Chakraborty, Stacey Tannenbaum, Andrew M. Wright and Christiane Rordorf
Beschreibung
Zusammenfassung:Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease/chronic infantile neurological cutaneous and articular syndrome (NOMID/CINCA) with etiology linked to mutations in the NLRP3 gene resulting in elevated interleukin-1β (IL-1β) release. CAPS is a rare hereditary auto-inflammatory disease, which may start early in childhood and requires a life-long treatment. Canakinumab, a fully human anti-IL-1β antibody, produces sustained selective inhibition of IL-1β. This study was conducted to assess the efficacy, safety, and pharmacokinetics of canakinumab in the treatment of pediatric CAPS patients.
Beschreibung:Gesehen am 11.07.2022
Beschreibung:Online Resource
ISSN:1465-9913
DOI:10.1186/ar3266

Ähnliche Einträge